TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* circulatory failure requiring norepinephrine support (any dose)~* hospitalization within an Intensive Care Unit~* SIRS~* low plasma albumin (\< 20g/L)~* consent to study~Exclusion Criteria:~* absence of circulatory failure~* absence of SIRS~* chronic low albumin concentration~* absence of consent to study~* inability to tolerate human serum albumin~* Patients under guardianship or curators~* Women pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous low dosage (CLD) (Type: EXPERIMENTAL): The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
- Intermittent high dosage (IHD) (Type: ACTIVE_COMPARATOR): The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bifeprunox in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Main inclusion criteria~* The subject has a primary diagnosis of schizophrenia~* The subject experiences clinically significant symptoms~* The subject's medication remained stable for 8 weeks prior to screening~* The subject is currently in the post-acute maintenance phase of his/her disease~Exclusion Criteria:~Main exclusion criteria~* The subject is at significant risk of suicide~* The subject is treatment resistant~* The subject has experienced an acute exacerbation within 8 weeks prior screening~* The subject is unlikely to comply with the protocol~* The subject has a current diagnosis or a history of substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bifeprunox (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Quetiapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Spectroscopic Imaging at 4T: A Drug Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be male volunteers between the ages of 21-45~* Non-smoking participants are preferred, but will admit those who smoke less than 5 cigarettes per day~* Participants must be able to read screening materials including consent form and give informed consent~Exclusion Criteria:~* Participants cannot meet DSM-IV criteria for lifetime and/or current mood, anxiety, psychotic, and alcohol/drug use disorders as identified by the SCID~* Participants cannot be taking any prescription medication (except oral contraceptives, certain short-term anti-fungal agents, and some topical creams for dermal conditions) or nutritional supplements~* Participants cannot be taking any psychotropic medications~* Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders.~* Participants cannot have any conditions that are contraindicated for MRI~* Participants cannot have a family history of alcoholism~* Participants cannot have any abnormal blood chemistries/urinalysis results or any other medical condition that may affect drug disposition (e.g., Hepatitis C)~* Participants cannot have current or past cardiac problems, and they also cannot have a family history of sudden death or ventricular arrhythmia~* Participants who, in the investigators' judgment, will not likely be able to comply with the study protocol.~* Participants cannot have any clinically significant findings in the structural anatomic brain scans (per the MRI report read by a board-certified radiologist).

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Alprazolam (A) (Type: ACTIVE_COMPARATOR): Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
- Dextroamphetamine (D) (Type: ACTIVE_COMPARATOR): Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
- Placebo (P) (Type: PLACEBO_COMPARATOR): Placebo gel-capsule, single-dose, 1-day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Steatosis~* ALT \>1.5 times normal~* ALT/AST ratio \>1.0~* Normal Kidney Function~Exclusion Criteria:~* Normal ALT within last 6 months~* Advanced fibrosis based on 1) biopsy, if available (Stage 3 or 4 NAFLD), 2) imaging, or 3) lab (platelet count \<150,000)~* Daily alcohol use above 20 g/day for women and 30 g/day for men~* Prescription use of ursodiol, ezetimibe, vitamin E, fish oils, thiazolidinediones, insulin, sulfonylureas, HMG-CoA reductase inhibitors~* Weight loss greater than 15% in past 12 months~* Pregnant or breastfeeding~* Body Mass index greater than 50~* Largest body circumference greater than 160 cm~* Claustrophobia~* Allergy to ezetimibe or ursodiol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EZ-URSO Combination Therapy (Type: EXPERIMENTAL): Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age~* Previously identified renal mass with radiology and clinical features consistent with RCC~* Clinical care plan includes partial or total nephrectomy~Exclusion Criteria:~* Less than 18 years of age~* Currently pregnant~* Renal mass with clinical care plan that does not include nephrectomy~* Renal mass suspected to be non RCC neoplasm by imaging and clinical data~* Renal mass unable to be visualized by grayscale ultrasound~* Known renal vein thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal malignancy (Type: EXPERIMENTAL): Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients over 6 months old with obstructive hydrocephalus who are referred for planned endoscopic third ventriculocisternostomy~Exclusion Criteria:~* MRI contraindication, non obstructive hydrocephalus, life expectancy inferior of 3 months, ETV in emergency, hydrocephalus aetiology interaction with hypothalamic-pituitary hormones, hydrocephalus already treated, basilar artery malformations, to be allergic to tetracosactide (synacthene) and to benserazide (Levodopa).

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- obstructive (Type: None): obstructive hydrocephalus in children and adults with biological evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Implantation of Markers for the Radiotherapy of Lung Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of non-small cell lung cancer~  * Stage I-IIIB disease~* No prior surgical tumor resection~* Respiration-induced tumor motion \> 5 mm~* Recruited by attending physician or research nurse at the Medical College of Virginia Hospitals~PATIENT CHARACTERISTICS:~* Not pregnant~* No insufficient lung function or other parameters prohibiting a bronchoscopy~* Not a prisoner or institutionalized~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Concurrent chemotherapy allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (Type: EXPERIMENTAL): Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mandibular Furcation III Regeneration (FURC-III-REGEN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ≥ 20 years~* Subject must have periodontal disease as determined by the World Workshop 2017 criteria~* Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD \>4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level~* Competent to give consent~Exclusion Criteria:~The following must not be present at the time of enrolment;~* Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment~* Present or past use of bisphosphonate treatment~* Pregnant or nursing subjects~* Patients classified as \> class 2 according to the ASA (American Society of Anesthesiologists) physical status classification~* Previous surgical therapy of included furcation defects~* Inability to comprehend and respond to the quality of life questionnaire~* Dental restorations or prosthesis involving the furcation area~* Root fractures or suspected infractions~* Caries lesions in the furcation area~* No systemic antibiotic treatment within 3 months prior to intervention

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Regenerative therapy w/BCP and collagen membrane (Type: EXPERIMENTAL): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
- Regenerative therapy w/BCP and enamel matrix proteins (Type: ACTIVE_COMPARATOR): In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical findings highly suggestive of advanced ovarian epithelial cancer undergoing surgery for definitive diagnosis and staging~* ≥ 65 years of age~Exclusion Criteria:~* Prior diagnosis of ovarian cancer~* Inability to read and speak English~* Inability to comply with study requirements

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically or cytologically confirmed prostate cancer.~2. Patients must have localized prostate cancer and have decided to undergo a prostatectomy or brachytherapy.~3. Patient must not be taking supplemental vitamin E.~4. Age \>18 years.~5. Life expectancy of greater than 6 months.~6. ECOG performance status =\< 2.~7. Patients must have normal organ and marrow function as defined below:~   * leukocytes \>= 3,000/mcL~  * absolute neutrophil count \>=1,500/mcL~  * platelets \>=100,000/mcL~  * total bilirubin within normal institutional limits~  * AST/ALT =\< 2.5 X institutional upper limit of normal~  * creatinine =\< 1.5 X normal institutional upper limit of normal~  * INR =\<1.4~  * PTT =\<1.4 X institutional upper limit of normal~8. Patients must have the ability to understand, and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients who have metastatic prostate cancer.~2. Patients may not be receiving any other investigational agents.~3. Patients with a known bleeding diathesis or patients on therapeutic anticoagulation. (This does not include the use of aspirin but refers to warfarin, heparin, or low molecular weight heparins).~4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin E.~5. The patient may not receive a gonadotrophin release agonist (such as goserelin, or leuprolide), or an antiandrogen (such as bicalutamide, flutamide, or nilutamide) during the study.~6. Uncontrolled intercurrent illness that would limit compliance with study requirements.~   * Inclusion of Women and Minorities~     * Only men are eligible for this trial. Members of all races and ethnic groups are eligible for this trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Vitamin E) (Type: EXPERIMENTAL): Vitamin E
- Arm 2 (Type: PLACEBO_COMPARATOR): Placebo (same vehicle as used for vitamin E)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetic patients in women\> 60 yo or men \> 55 yo, with high risk of coronary artery disease (EF \< 40%, ECG abnormalities, renal failure , 2 others risk factors of atherosclerosis)~Exclusion Criteria:~* previous documented CAD acute coronary syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): SPECT
- 2 (Type: None): dobutamine echocardiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Safety and Efficacy of CT ASPHINA 509 Lenses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;~* Patients of any gender~* Assured follow-up examinations~* Biometry measurement preferably compatible with the IOLMaster evaluation;~* IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in one eye with at least 12 months follow up at the time of the postop visit~* Patients who had uncomplicated (no peroperative complication) agedrelated cataract surgery in a healthy eye (beside clinically significant cataract)~Exclusion Criteria:~* • BCVA not available preoperatively or better than 0.3 logMAR pre-op~  * Patients unable to meet the limitations of the protocol or likely of noncooperation during the trial~ * Patients whose freedom is impaired by administrative or legal order~ * Concurrent participation in another drug or device investigation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 509 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Home-Based Exercise Program for Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~On program at Catholic Home Care (CHC) Have a diagnosis of CHF NYHA II or III Medically stable 60 - 85 years of age at completion of study Able to follow commands Normal vision (with corrective lenses, if necessary) Willing to participate in a program for 1 year Have a reliable caregiver that is willing to assist as necessary -~Exclusion Criteria:Latex allergy, Unstable CHF NYHA IV Pain that interferes with activity Active neurological and or orthopedic problems, Cancer, End stage renal disease Decreased balance as indicated on Tinetti balance assessment \< 10/16.~-

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Resistive Training (Type: EXPERIMENTAL): Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue \~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues